STOCK TITAN

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Palatin Technologies, Inc. (PTN) will release its Q2 fiscal year 2024 operating results on February 15, 2024, with a conference call and webcast to follow. The call will cover the company's results and ongoing programs.
Positive
  • None.
Negative
  • None.

CRANBURY, N.J., Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast


Q2 Fiscal Year 2024 Results Press Release

2/15/2024 at 7:30 a.m.ET



Q2 Fiscal Year 2024 Conference Call-Live

US Toll Free Dial-In Number:

International Dial-In Number:

Participant Access Code:

2/15/2024 at 11:00 a.m. ET

1-888-506-0062

1-973-528-0011

397299



Q2 Fiscal Year 2024 Conference Call-Replay 

US Toll Free Dial-In Number: 

International Dial-In Number:

Participant Access Code: 

2/15/2024-2/29/2024

1-877-481-4010

1-919-882-2331

49945

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.

About Palatin 
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-second-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-held-on-february-15-2024-302058387.html

SOURCE Palatin Technologies, Inc.

FAQ

When will Palatin Technologies release its Q2 fiscal year 2024 operating results?

Palatin Technologies will release its Q2 fiscal year 2024 operating results on February 15, 2024.

What time will the conference call and audio webcast be held on February 15, 2024?

The conference call and audio webcast will be held at 11:00 a.m. ET on February 15, 2024.

Where can investors access the audio webcast and replay?

Investors can access the audio webcast and replay on Palatin's website under the 'Investors-Webcasts' section or by visiting http://www.palatin.com.

What are the dial-in numbers for the conference call on February 15, 2024?

The US Toll-Free Dial-In Number is 1-888-506-0062, and the International Dial-In Number is 1-973-528-0011.

What is the Participant Access Code for the conference call on February 15, 2024?

The Participant Access Code is 397299 for the conference call on February 15, 2024.

Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Latest News

PTN Stock Data

30.18M
15.54M
3.35%
10.72%
9.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CRANBURY

About PTN

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy